SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| GLYXAMBI | 25,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 226.05 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
| GLYXAMBI | 10,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 226.05 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| GLYXAMBI | 10MG;5MG; 25MG;5MG | tablet · oral | BOEHRINGER INGELHEIM | Prescription | 30 Jan 2015 |
EMA European Union — centrally authorised medicines
Glyxambi Boehringer Ingelheim International GmbH · Authorised · authorised 11 Nov 2016 · ATC A10BD19
Therapeutic indication (EMA)
Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control; when already being treated with the free combination of empagliflozin and linagliptin.
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | GLYXAMBI 10 MG-5 MG TABLET | $11.24368 | per EA | 23 Sep 2026 |
| US NADAC | GLYXAMBI 25 MG-5 MG TABLET | $11.19937 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Empagliflozin 10mg / Linagliptin 5mg tablets | £55.88 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Empagliflozin 25mg / Linagliptin 5mg tablets | £55.88 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.